Biotech Investment Analyst — Drug Asset & Company Assessment
$120–$200/hr
New to Mercor? Create an account before applying.
Get new roles by emailFollow on X
Jobs › Science & Research › Mercor
- Pay
- $120 to $200 per hour
- Pay type
- Hourly
- Platform
- Mercor
- Field
- Science & Research
- Where
- Remote
- First seen
- Posted
- History
- Half of Mercor roles listed since Oct 2 were gone within 28 days (of 329). How long roles stay open
- Feed read
This listing comes from Mercor's own public job feed. The posting on Mercor is the source of truth.
About the role
Mercor is partnering with a biotech and pharma research team on expert human-evaluation work — creating and critiquing rubrics that analyze commercial drugs and drug-development programs. We're seeking a biotech investment analyst (specialist-fund background) for a paid pilot, with the potential to continue as the work scales.
Responsibilities
- Create and critique rubrics that analyze commercial drugs and drug-development programs
- Provide overall company and asset assessment — mechanism, clinical data, competitive position, and value drivers
- Judge the quality of an investment-style thesis and flag weak, overconfident, or missing assumptions
- Apply your assessment across the pilot's set of companies (~5–10)
Requirements
- US-based biotech / healthcare investment analyst with a specialist-fund background
- Familiarity with biotech/pharma development programs
- Able to assess a drug asset and the company behind it end-to-end
- 5+ years evaluating biotech/pharma companies or assets
Engagement Details
- Duration: Approximately 10–20 hours over a 1–2 week pilot
- Remote — US-based
Why Participate
- Help improve expert AI evaluation of drugs and drug-development programs
- Recurring engagement for strong contributors